Overview
We are focused on developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases.
We have two ongoing clinical trials to evaluate an investigational study drug, pacibekitug (also referred to as TOUR006): one for the treatment of thyroid eye disease (TED) and the other for the treatment of atherosclerotic cardiovascular disease (ASCVD).
TED is an autoimmune disease characterized by autoantibodies targeting the eye’s surrounding tissue, leading to inflammation, swelling, and tissue remodeling. TED can cause significant discomfort and disfigurement and can be sight-threatening if left untreated.
ASCVD is a group of conditions caused by plaque buildup in the artery walls and includes myocardial infarctions (heart attacks) and strokes. Despite current treatment options, millions remain at very high risk of heart attack, stroke, acute limb ischemia, and death; ASCVD-related conditions are a leading cause of death worldwide
Pacibekitug is a long-acting, fully human monoclonal antibody with best-in-class potential and differentiated properties, including a naturally long half-life, low immunogenicity, and high binding affinity to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory diseases. Tourmaline is developing pacibekitug with the potential to be administered by a low volume, subcutaneous injection (not infusion) as infrequently as once every quarter.
The spiriTED study is evaluating an investigational study drug, pacibekitug, to see how it works in adults with TED.
Trial Status: Actively recruiting
Trial Information: spiriTED is a multicenter, randomized, double-masked, placebo-controlled, dose-ranging, Phase 2b study of pacibekitug in participants with Thyroid Eye Disease
For more information, visit ClinicalTrials.gov Identifier: NCT06088979
For information about our expanded access policy, please view here.
Learn more about pacibekitug in TED.
Learn more about the science of pacibekitug.
The TRANQUILITY trial is evaluating an investigational study drug, pacibekitug, to see how it works in adults with elevated high-sensitivity C-reactive protein (hs-CRP) and chronic kidney disease (CKD), who have a heightened risk of ASCVD including heart attack, stroke, and peripheral artery disease, despite current standard-of-care treatments.
Trial Status: Actively recruiting
Trial Information: TRANQUILITY is a multicenter, randomized, double-masked, placebo-controlled Phase 2 study designed to evaluate the safety, pharmacokinetics, and pharmacodynamics, including CRP-lowering effect, of quarterly and monthly subcutaneous administration of pacibekitug in patients with inflammatory risk, manifesting as elevated hs-CRP and CKD.
For more information, visit ClinicalTrials.gov Identifier: NCT06362759
For information about our expanded access policy, please view here.
Learn more about pacibekitug in ASCVD.
Learn more about the science of pacibekitug.
